Lp(a) Drug Falls Short on Heart Outcomes | Huntsville News

Novartis’ experimental heart drug pelacarsan slashed dangerous Lp(a) levels in massive trials—but shockingly failed to prevent heart attacks, strokes, or deaths, shattering a core assumption in cardiology and casting doubt on the entire field’s rush to target this genetic risk factor. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/21832962f96668af